This miniperspective highlights key advances inthe development of topical PROTACs, exemplified by AH-001 and GT20029, androgen receptor degraders, both in clinicaltrials for androgenetic alopecia, with GT20029 also evaluatedfor acne. Here, AR is linked to acne.